Request More Information
Simoa® Cardiology Assays & Services
From discovery to diagnostics, our Simoa assays and custom assay development services can fuel your research through the ability to identify and examine critical biomarkers less invasively, more efficiently, and with higher accuracy when compared to other analog methods.
Simoa assays can detect neurological biomarkers, such as NfL and GFAP in blood, serum or plasma. These markers, previously quantifiable in CSF only, can be detected at ultra-low levels using Simoa and have the potential to predict neurological outcomes in cardiac event patients. The prognostic utility of biomarkers, such as NfL, could play a critical role in long and short-term prognoses of neurological outcomes after major cardiac events and in monitoring patients who undergo cardiopulmonary bypass.
Jump to form ↓ |